Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

H Lu, Q Zhou, J He, Z Jiang, C Peng, R Tong… - Signal transduction and …, 2020 - nature.com
Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed
that aberrant PPIs are associated with various diseases, including cancer, infectious …

Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease

P Hermann, B Appleby, JP Brandel, B Caughey… - The Lancet …, 2021 - thelancet.com
Summary Sporadic Creutzfeldt-Jakob disease is a fatal neurodegenerative disease caused
by misfolded prion proteins (PrP Sc). Effective therapeutics are currently not available and …

Modulators of 14-3-3 protein–protein interactions

LM Stevers, E Sijbesma, M Botta… - Journal of medicinal …, 2017 - ACS Publications
Direct interactions between proteins are essential for the regulation of their functions in
biological pathways. Targeting the complex network of protein–protein interactions (PPIs) …

Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival

E Emmanouilidou, K Melachroinou… - Journal of …, 2010 - Soc Neuroscience
α-Synuclein is central in Parkinson's disease pathogenesis. Although initially α-synuclein
was considered a purely intracellular protein, recent data suggest that it can be detected in …

NMDAR hypofunction animal models of schizophrenia

G Lee, Y Zhou - Frontiers in molecular neuroscience, 2019 - frontiersin.org
The N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis has been proposed to
help understand the etiology and pathophysiology of schizophrenia. This hypothesis was …

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization

RJ Nichols, N Dzamko, NA Morrice… - Biochemical …, 2010 - portlandpress.com
LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant number of
Parkinson's disease patients, but still little is understood about how it is regulated or …

Modulation of protein–protein interactions for the development of novel therapeutics

I Petta, S Lievens, C Libert, J Tavernier… - Molecular Therapy, 2016 - cell.com
Protein–protein interactions (PPIs) underlie most biological processes. An increasing
interest to investigate the unexplored potential of PPIs in drug discovery is driven by the …

Unlocking the code of 14-3-3

MK Dougherty, DK Morrison - Journal of cell science, 2004 - journals.biologists.com
One of the most strikingrags to riches' stories in the protein world is that of 14-3-3, originally
identified in 1967 as merely an abundant brain protein. The first clues that 14-3-3 would play …

14-3-3 proteins are on the crossroads of cancer, aging, and age-related neurodegenerative disease

X Fan, L Cui, Y Zeng, W Song, U Gaur… - International journal of …, 2019 - mdpi.com
14-3-3 proteins are a family of conserved regulatory adaptor molecules which are expressed
in all eukaryotic cells. These proteins participate in a variety of intracellular processes by …

14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking

MP Rubio, KM Geraghty, BHC Wong… - Biochemical …, 2004 - portlandpress.com
14-3-3-interacting proteins were isolated from extracts of proliferating HeLa cells using 14-3-
3 affinity chromatography, eluting with a phosphopeptide that competes with targets for 14-3 …